continuous response variables were analyzed using χ 2 tests and analysis of covariance, respectively. We report no significant associations following correction for multiple testing. Prior to correction, nominally significant associations were observed for SLC6A9 , SLC1A2 , GRM2 , and GRIA1 . Most notably, CC homozygotes of rs16831558 located in the glycine transporter 1 gene (SLC6A9) exhibited an allele dosedependent improvement in positive symptoms compared to T allele carriers (p uncorrected = 0.008, p corrected = 0.08). To clarify the role of SLC6A9 in clinical response to antipsychotic medication, and CLZ in particular, this finding warrants further investigation in larger well-characterized samples.
Introduction
The glutamate system has emerged as an area of strong interest in both schizophrenia (SCZ) risk and response to antipsychotic (AP) medications [1] . The glutamate hypothesis of SCZ first emerged from observations that ad-ministration of N-methyl-D -aspartate glutamate receptor (NMDAR) antagonists such as phencyclidine and ketamine elicit behaviors that mimic the symptoms of SCZ in healthy individuals and dramatically worsen symptoms in SCZ patients [2] [3] [4] [5] . Glutamate levels also appear to be altered in SCZ brains, and dysregulation of glutamate receptors has been postulated to play an integral role in the hyperdopaminergic states often thought to be the primary cause of psychosis [6] .
Clozapine (CLZ) is an atypical AP drug that is particularly effective for treating patients with treatment-resistant SCZ (TRS) [7] . Approximately 30% of patients fail two or more trials with AP drugs, and are subsequently diagnosed with TRS. For these individuals, CLZ is the one drug that has been approved for treatment of this particular subpopulation of patients [8] [9] [10] . Response to CLZ is complex and thought to depend, at least in part, on genetic factors, as indicated by twin and family studies [11] [12] [13] [14] . Like other APs, high interindividual variability is also observed with CLZ treatment [15] [16] [17] , with up to 50% of eligible patients failing to respond [7, 18] . Studies in pharmacogenetics aim to identify gene variants with the potential to predict dosing, response, and side effects prior to starting drug treatment [19] . The implications of a genetic test incorporating such variants would have farreaching clinical applications; given the fact that early and effective treatment has been associated with favorable outcome [20, 21] . To date, the majority of pharmacogenetic studies investigating CLZ response have focused on gene variants in dopamine and serotonin neurotransmitter pathways [reviewed in 22 ] .
As noted, there is mounting evidence to suggest that glutamatergic neurotransmission may also play a role in mediating response to CLZ [ 23 , reviewed in 24 ] . The main observation supporting this hypothesis is that if CLZ is coadministered with NMDAR antagonists, their psychotomimetic effects are blunted [25] . Glutamate concentrations and excitatory glutamate neurotransmission are also increased by CLZ administration, as shown by microdialysis studies in rodents [26, 27] , excitatory postsynaptic potentials in neuronal cell cultures [28] [29] [30] [31] [32] , and increased serum glutamate levels in patients switched to CLZ [33] .
CLZ is also posited to modulate various receptors, transporters, and enzymes involved in glutamate signaling, consequently implicating single nucleotide polymorphism (SNP) gene variants within these pathways as strong candidates for assessing susceptibility to CLZ nonresponse. In regard to glutamate receptors, CLZ administration increases α-amino-3-hydroxy-5-methyl-4-isoxazole propionic acid (AMPA) receptor density and AMPA receptor subunit 1 (GluR1) expression [34, 35] . The GluR1 subunit protein is encoded by the GRIA1 gene mapped to 5q31.1 [36] . CLZ also increases metabotropic glutamate receptor 2 (mGluR2) signaling [37] , which is encoded by the GRM2 gene mapped to 3p21.1 [38] . AMPA and mGluR glutamate receptors are involved in primary depolarization of glutamate-mediated neurotransmission and synaptic plasticity [39, 40] .
With respect to transporter proteins, CLZ reportedly downregulates expression of glutamate transporter 1 (GLT1) in the rat cerebral cortex [41] . GLT1, encoded by the SLC1A2 gene that maps to region 11p13-p12 [42] , localizes to astrocytes in the mammalian CNS and is responsible for the greatest proportion of total glutamate reuptake from the synapse [43] . Functional inactivation of GLT1 raises extracellular glutamate levels, a biological phenomenon implicated in AP nonresponse [44] . CLZ also increases synaptic glycine concentrations [45] . In neuronal tissue, the glycine transporter 1 (GlyT1) chiefly determines the availability of glycine in the brain by mediating glycine reuptake into surrounding nerve terminals and glial cells [46] . The SLC6A9 gene codes for GlyT1 and is mapped to 1p33 [47] .
Lastly, CLZ has been shown to downregulate promoter methylation of the glutamate decarboxylase 1 (GAD1) enzyme in mice [48] . GAD1 catalyzes the decarboxylation of glutamic acid to the inhibitory neurotransmitter GABA (γ-aminobutyric acid) and carbon dioxide [49] and is encoded by the GAD1 gene that maps to 2q.31 [50] . Interestingly, abnormal GABAergic function is also reported in patients with SCZ [51] .
Based on the aforementioned body of evidence, the present study set out to investigate the contribution of glutamate variants distributed in the genes SLC1A2 , SLC6A9 , GRIA1 , GRM2 , and GAD1 to CLZ response in a sample of subjects with TRS or treatment intolerance to other APs.
Subjects and Methods

Study Sample
Subjects included in this study were recruited from three clinical sites: Case Western Reserve University in Cleveland, Ohio (H.Y.M., n = 74); Hillside Hospital in Glen Oaks, N.Y. (J.A.L., n = 73), and University of California, Irvine, Calif. (S.G.P., n = 28) (total sample, n = 175). All patients had a diagnosis of SCZ or schizoaffective disorder according to the Diagnostic and Statistical Manual for Mental Disorders III-R or IV (DSM-III-R/IV) [52, 53] and met criteria for either TRS or intolerance to standard pharmacotherapy. TRS was defined as failure to respond to 2 or more AP trials with drugs from at least 2 different chemical classes at doses of ≥ 1,000 mg/day chlorpromazine equivalents for 4-6 weeks, together with no period of good functioning in the preceding 5 years [7] . A smaller portion of patients (<15%) met criteria for treatment intolerance defined as the presence of moderate-to-severe tardive dyskinesia or extreme sensitivity to extrapyramidal symptoms [18] .
For the genetic studies, written informed consent was obtained from all study participants in accordance with the Ethical Principles for Medical Research Involving Human Subjects at the Centre for Addiction and Mental Health (CAMH) and with the Declaration of Helsinki as revised in 1989 [54] . Study participants underwent a 2-to 4-week washout period during which no medication was administered unless clinically necessary. During the washout period, benzodiazepines were the only class of drugs permissible in cases where treatment was clinically necessary; however, they were used sparingly. The patients were then placed on CLZ monotherapy for 6 months or longer with mean doses in the range of 450 mg/day. Benzodiazepines were the only class of drugs administered intermittently during the titration period. For the duration of the study, the patients were seen weekly for blood draws to monitor white blood cell/neutrophil counts as a precaution against CLZ-induced agranulocytosis.
Response Measures CLZ response was assessed using both categorical and continuous response measures. Categorical response was assessed using change in Brief Psychiatric Rating Scale (BPRS) scores between baseline and following 6 months of CLZ therapy. Participants were considered responders if they experienced a ≥ 20% decrease in 
SNP Selection
In total, 10 glutamate gene variants were included in our study ( table 1 ) . Four variants were selected based on previous investigation into other neuropsychiatric phenotypes as cited in the literature, and the remaining 6 were selected from several functional annotation websites based on potential to alter gene expression.
Identification of SNPs from the Literature. A literature search was conducted on PubMed using the following search terms:
, and 'Glutamate Decarboxylase 1'. Articles investigating genetic associations (genome-wide and candidate SNP studies) with neuropsychiatric phenotypes were considered. In addition, articles investigating the functional significance (positron emission tomography ligand binding assays, electrophoretic mobility shift assays, luciferase promoter assays, etc.) of variants within SLC1A2 , SLC6A9 , GRIA1 , GRM2 , and GAD1 were reviewed to identify glutamate system SNPs of interest.
Identification of SNPs with Potential Functionality. The Broad Institute's HaploReg database (http://www.broadinstitute.org/ mammals/haploreg/haploreg.php) was used to identify glutamate variants with potentially functional effects on gene expression ( fig. 1 ) [55] . The genes' coding regions, plus an additional 10 kb upstream and 2 kb downstream, were submitted to the 'Build Query' search field on HaploReg. Gene regions (chrN:start-end) were obtained from the UCSC (University of California Santa Cruz) Genome Browser using Human Genome assembly version 19: GRM2 (chr3: 51,731,081-51,754,625), SLC1A2 (chr11: 35,270,752-35,461,610), SLC6A9 (chr1: 44,455,172-44,507,164), and GRIA1 (chr5: 152,849,175-153,088,732). Seven criteria for measuring functionality were provided for each SNP: (1) sequence conservation across mammals, (2) promoter histone marks, (3) enhancer histone marks, (4) DNAse hypersensitivity sites, (5) bound proteins, (6) expression quantitative trait locus data, and (7) the effect on regulatory motifs. SNPs with a minor allele frequency of ≥ 5% in the European population that satisfied ≥ 3 of the 7 functional criteria were considered for inclusion. Six variants satisfying these criteria were selected: SLC1A2 (rs2901534), SLC6A9 (rs12037805, rs1978195, and rs16831558), GRIA1 (rs2195450), and GRM2 (rs2518461) ( fig. 2 ). RegulomeDB [56] and the National Institute of Environmental Health Sciences (NIEHS) Functional SNP Prediction (FuncPred) database scores [57] were also obtained to further assess functionality.
DNA Isolation and Genotyping
Venous blood samples were collected from the study participants and sent to our center (CAMH, Toronto, Ont., Canada), where genomic DNA was extracted using the high salt method [58] . Genotyping was performed using the QuantStudio 12K Flex Real-Time PCR System (Applied Biosystems, Foster City, Calif., USA). The final PCR reaction mixtures consisted of 20 ng of genomic DNA and 2 μl of 2× TaqMan ® OpenArray ® Genotyping Master Mix. Samples were loaded onto a QuantStudio Digital PCR Plate using the QuantStudio 12K Flex AccuFill System and run on the QuantStudio 12K Flex Instrument as per the manufacturer's instructions. Genotype calls were visualized using the DigitalSuite Software and were validated by two independent researchers blinded to the genotyping conditions. To ensure genotyping accuracy, 10% of the samples were re-genotyped, and conflicting genotypes were set as missing for future analyses.
Statistical Analyses
Quality control (QC) of the genotyping data was carried out using PLINK v1.07 [59] . In order to pass QC, SNPs were required to have a ≥ 90% genotyping rate, to have a minor allele frequency of ≥ 0.05, and to satisfy the Hardy-Weinberg equilibrium (p > 0.005). In addition, individuals with a genotyping efficiency <80% across all markers (samples producing genotypes for ≤ 7 SNPs) were excluded from analysis.
Descriptive statistics were carried out using the Statistical Package for the Social Sciences (SPSS) v20 (IBM Corporation, Armonk, N.Y., USA). Continuous variables were analyzed using Student's HaploReg database results for 6 putatively functional variants included in this study [55] . To be considered for study inclusion, variants were required to have a minor allele frequency of ≥ 5% and to satisfy ≥ 3 of 7 functionality criteria. Chr = Chromo- t test or analysis of variance (ANOVA), and categorical variables were analyzed using Pearson's χ 2 test. Genotype and allele frequencies in the responder/nonresponder groups were compared using the χ 2 test, or by Fisher's exact test for cell counts <5. Differences in percent score reductions in the BPRS and the BPOS and BNEG subscales among genotype groups were compared using analysis of covariance (ANCOVA), with age and baseline scores added as covariates.
The Hardy-Weinberg equilibrium and the linkage disequilibrium (LD) among SNPs were determined using Haploview v4.2 and the Solid Spine of LD to construct LD blocks ( fig. 3 ) [60] . Haplotype analyses were carried out using UNPHASED v3.1.5, and haplotype p values were corrected for multiple testing using permutation (10,000 tests) [61] . Haplotypes with a frequency <0.05 were removed from subsequent analyses. Power calculations were performed using Quanto v1.2.4 [62] . Multiple testing correction was performed using the Nyholt method and resulted in a revised statistical significance threshold of p < 0.005 [63] . 
Results
Study Sample Characteristics
Following the QC procedures, 12 individuals were removed due to low genotyping efficiency (<80% of the markers were successfully genotyped). The remaining sample had a mean genotyping efficiency of 98.9%. All SNPs met the QC criteria and had a mean genotyping rate of 99.3%. In total, 163 European treatment-resistant/ -intolerant patients were included in the analyses ( table 2 ). Our sample had >80% power to detect an odds ratio as low as 2.1 (unmatched case-control design, n = 163; nonresponder frequency = 47.2; minor allele frequency = 26.5%; α/2 = 0.05) and down to 8.5% of the variance in the quantitative response variable (continuous design, n = 91). The average minor allele frequency across the 10 glutamate variants was used for power calculations. Values are presented as means ± SD or n (%). SD = Standard deviation; R/NR = responders/nonresponders; BPRS = Brief Psychiatric Rating Scale; BNEG/BPOS = BPRS negative and positive subscales; NA = data not available.
a Responders defined as having a ≥20% reduction in BPRS scores from baseline. b p values from Student's t test or one-way ANOVA. c p values from χ 2 test. Among the three clinical sites, no statistically significant differences were observed for gender, response rates, or percent score reductions in the BPRS, BPOS, and BNEG scales. A statistically significant difference was observed, however, for age of the study participants across the clinical sites (p = 0.001). Post hoc analysis using Scheffé's test for unequal sample sizes revealed that patients originating from S.G.P.'s sample were significantly older than patients from H.Y.M.'s sample. Baseline BPRS, BPOS, and BNEG values were also correlated with their respective percent reduction scores. In order to combine the three samples for analysis, both age and baseline scores were included as covariates in the analyses of continuous response. The combined sample (n = 163) consisted of 74.8% males and had a mean age of 35.1 years (SD 8.1). Following 6 months of CLZ therapy, the patients experienced a mean percent reduction of -9.1 (SD 12.4), -1.1 (SD 3.6), and -3.2 (SD 5.7) from baseline for the BPRS, BNEG, and BPOS scales, respectively. In addition, 52.8% of the patients experienced a ≥ 20% decrease in BPRS scores and were subsequently classified as CLZ responders.
Glutamate System Variant Genotype and Allele Association Analyses
Following correction for multiple testing, no significant differences between the responder and nonresponder groups or as measured by change in percent scores using the BPRS, BPOS, and BNEG scales were observed for genotype and allele frequencies for each of the 10 glutamate system gene variants ( table 3 ) . A number of nominally significant associations were observed prior to correction; however, none were significant following correction for multiple testing.
SLC6A9 rs16831558 C allele carriers experienced an allele dose-dependent reduction (improvement) in BPOS subscale scores following 6 months of CLZ therapy (p uncorrected = 0.008, p corrected = 0.08) ( fig. 4 ) . CC homozygotes of rs16831558 also experienced a greater reduction in BPRS total scores (p uncorrected = 0.045, p corrected = 0.421). In addition, greater reductions in BNEG subscale scores were observed for 5 variants: SLC1A2 rs4534557 homozygotes (GG and CC; p uncorrected = 0.015, p corrected = 0.140), GRIA1 rs2195450 A allele carriers (p uncorrected = 0.017, p corrected = 0.162), SLC1A2 rs4354668 TT homozygotes C allele carriers of the SLC6A9 variant rs16831558 experienced an allele dose-dependent reduction in BPOS scores following 6 months of CLZ therapy (p uncorrected = 0.008, p corrected = 0.08, assuming 9.36 independent tests); however, this finding did not remain significant following correction for multiple testing.
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GRM2 and SLC6A9 Haplotype Analyses
No haplotype blocks within GRM2 rs4067-rs2518461 were significantly different between responder/nonresponder groups, or in regard to continuous response measures ( table 4 ) . Initially, the haplotype block rs16831558-rs12037805-rs1978195 T-T-A within SLC6A9 appeared significantly associated with change in BPOS scores following CLZ treatment (p uncorrected = 0.001, p corrected = 0.006, permutation corrected, individual haplotype effect). However, further investigation revealed that the positive association was driven solely by the rs16831558 marker; the SLC6A9 rs12037805-rs1978195 haplotype, when analyzed independently with the rs16831558 variant added as a conditioning marker, was no longer significant ( table 5 ) .
Discussion
This investigation explored the association between 10 glutamate system gene variants and clinical response to CLZ. No significant associations were observed following correction for multiple testing in our sample of patients. To our knowledge, though, this is the first reported study to investigate the role of SLC1A2 (rs4354668, rs4534557, and rs2901534), SLC6A9 (rs12037805, rs1978195, and rs16831558), GRIA1 (rs2195450), GRM2 (rs4067 and rs2518461), and GAD1 (rs3749034) in response to CLZ. Four of these variants had previously been investigated in other neuropsychiatric phenotypes, while the remaining 6 were previously unstudied SNPs selected using HaploReg.
Several nominally significant associations of SLC6A9 , SLC1A2 , GRM2 , and GRIA1 with CLZ response were observed before correcting for the number of independent tests. Of interest was the association between C allele carriers of SLC6A9 rs16831558 and percent score reduction in the BPOS subscale (p uncorrected = 0.008). Individuals carrying two copies of the C allele showed a 4.25% decrease in severity of positive symptoms, while those carrying one copy experienced no symptom change, and individuals with two copies of the T allele experienced worsening of their positive symptoms, as indicated by BPOS scores that were approximately 3.00% higher than the scores obtained at baseline. This finding became nonsignificant following correction (p corrected = 0.08), but given our relatively small sample size, this nominally significant finding for SLC6A9 rs16831558 may deserve further investigation in larger CLZ response samples.
The SLC6A9 locus is particularly complex, with 16 different mRNA transcripts and 14 different splice variants [64] . The rs16831558 variant reported herein is located approximately 5 kb upstream of the SLC6A9 start site. This variant has a RegulomeDB [56] functional score of 2b ('likely to affect binding') and is predicted to lie within an enhancer histone mark, a DNAse I hypersensitivity site, and to affect regulatory motifs [55] . Therefore, characterization of this SNP's potential functionality using mobility shift and luciferase promoter assays may be a priority for future work.
GlyT1 has recently been the focus of several novel therapies for SCZ [65] . One of the most developmentally advanced drugs is bitopertin (RG1678), a synthetic GlyT1 inhibitor developed by Roche. Five phase III clinical trials have been conducted to investigate bitopertin as an adjunct to conventional AP therapy for the treatment of persistent negative symptoms or partial responders, although the results are nonsignificant (ClinicalTrials.gov identifiers: NCT01192867, NCT01192906, NCT01192880, NCT01235520, and NCT01235559). Biologically, GlyT1 regulates extracellular glycine concentrations in the vicinity of excitatory glutamatergic synapses [66] . Glycine, in turn, acts as a necessary co-agonist at the NR1 subunit and promotes NMDAR function [67, 68] . GlyT1 inhibitors block glycine reuptake from the synapse, causing an increase in NR1 glycine site occupancy and NMDAR potentiation, thus ameliorating the NMDAR hypofunction thought to contribute to SCZ etiology.
Following the same rationale, various NR1 glycine site agonists including glycine, D -serine, and D -cycloserine have been investigated as adjuncts to conventional AP therapy for treating persistent negative and cognitive symptoms in SCZ [reviewed in 69 ]. Even though glycine agonist drugs are not designed to improve the positive symptoms seen in TRS patients, observations of their use in clinical studies to improve negative symptoms have shed light on a possible action of CLZ on the glycine system: NR1 glycine agonists are generally well received when paired with most APs, but they provide little therapeutic benefit and may in fact worsen symptoms when administered to patients taking CLZ [23, 70] . This incompatibility between NR1 agonists and CLZ may be due to CLZ's preexisting ability to potentiate NMDAR-mediated neurotransmission through an as yet unknown mechanism [71] . Several mechanisms have been posited; for instance, CLZ may already increase synaptic glycine levels [45] or may act as a partial agonist at the NR1 glycine site of the NMDAR [72] . Alternatively, CLZ's ability to alter dopamine activity and achieve therapeutic effects may depend in part on the availability of the NMDAR glycine site [73] . Future studies are necessary to clarify the role of glycine receptor gene variants in the mechanism of CLZ's action.
There are some limitations inherent in our study that deserve to be mentioned. Our small sample size may not have had sufficient statistical power to detect the effect sizes of these gene variants, and going forward the collection of larger samples will help determine the contribution of genetics to the phenotype of CLZ response. One such sample is currently being collected by the CRESTAR consortium in Europe [74] with the goal of identifying markers involved in CLZ response and side effects. Heterogeneity within our study sample may also have confounded association findings. The participants were collected from three clinical sites that may have differed in population substructure. In addition, the study inclusion criteria were relatively broad; for example, patients with a diagnosis of either SCZ or schizoaffective disorder were eligible for study inclusion.
Incomplete outcome data may also have limited our findings. Individuals who quit prior to study completion invariably affect response rates and may confound the ability to identify genetic variants linked to treatment response. Unfortunately, rates for treatment discontinuation in AP drug trials are estimated to be in the range of 40%, with common reasons for discontinuation including noncompliance, lack of efficacy, and adverse side effects [18, 75, 76] . In certain patients, response to CLZ may take up to 5 months or longer, suggesting that some participants who discontinue treatment because of lack of efficacy most likely do so prematurely. The high rates of discontinuation during AP drug trials stress the need for understanding the interindividual variability in drug response phenotypes and emphasize the utility associated with identifying clinically predictive markers.
To conclude, we report no significant associations between 10 glutamate system gene variants and response to CLZ in our sample following correction for multiple testing. A nominally significant association with the GlyT1 gene variant rs16831558 was observed prior to correction, and may deserve further examination in larger wellcharacterized CLZ response samples. Future work may consider investigating the potential for other gene variants in the glutamate system to alter response to CLZ, as well as the genetic effect of these variants on additional symptom domains such as cognition. 
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